ABSTRACT
OBJETIVO/MÉTODO: Presentamos una serie de 4 pacientes afectos de psoriasis ocular con sintomatología severa, a los que se indicó tratamiento off label con tacrolimus tópico al 0,03% una vez al día. Resultados/conclusión: La blefaritis mixta y queratitis es común a los 4, y en 3 casos hay seudopterigión y opacidades corneales. Se apreció mejoría subjetiva del prurito en 2 semanas, y al mes mejoría de la superficie. Todos manifiestan mejoría significativa de su calidad de vida tras un rango de seguimiento de 6 meses a 2 años. El tacrolimus tópico puede ser considerado una opción en el tratamiento de la psoriasis ocular
OBJECTIVE/METHODS: Cases are presented of 4 patients suffering from severe symptoms due to ocular psoriasis and who were treated with off-label 0.03% tacrolimus once a day. Results/conclusions: All four patients had a mixed blepharitis and keratitis. Pseudopterygium and corneal opacities were present in three of them. All of them experienced an improvement of their itching and ocular surface. They all referred to a marked improvement of their quality of life in a follow-up period ranging from six months to two years. Therefore, topical tacrolimus could be considered an option in the treatment of ocular psoriasis
Subject(s)
Humans , Male , Female , Aged , Psoriasis/complications , Psoriasis/drug therapy , Tacrolimus/administration & dosage , Tacrolimus/therapeutic use , Blepharitis/complications , Blepharitis/drug therapy , Keratitis/drug therapy , Pterygium/complications , Pterygium/drug therapy , Administration, Topical , Eye Diseases/complications , Eye Diseases/diagnosis , Eye Diseases/drug therapy , Quality of LifeABSTRACT
OBJECTIVE/METHODS: Cases are presented of 4 patients suffering from severe symptoms due to ocular psoriasis and who were treated with off-label 0.03% tacrolimus once a day. RESULTS/CONCLUSIONS: All four patients had a mixed blepharitis and keratitis. Pseudopterygium and corneal opacities were present in three of them. All of them experienced an improvement of their itching and ocular surface. They all referred to a marked improvement of their quality of life in a follow-up period ranging from six months to two years. Therefore, topical tacrolimus could be considered an option in the treatment of ocular psoriasis.
Subject(s)
Eye Diseases/drug therapy , Psoriasis/drug therapy , Tacrolimus/administration & dosage , Administration, Topical , Aged , Female , Humans , MaleABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Young Adult , Antiviral Agents/therapeutic use , Catechin/analogs & derivatives , Hand Dermatoses/drug therapy , Foot Dermatoses/drug therapy , Warts/drug therapy , Catechin/therapeutic use , Fingers , OintmentsABSTRACT
El prurito asociado a los fármacos inhibidores de la enzima convertidora de angiotensina (IECA) es un efecto secundario poco descrito en la literatura española. Presentamos 4 pacientes afectos de prurito generalizado debido al enalapril que cedió tras la suspensión del fármaco. Es importante identificar que una de las posibles causas de prurito persistente y prolongado en algunos pacientes es este tipo de fármacos (AU)
